论文部分内容阅读
目的探讨肾癌不同转移器官分子靶向治疗药物应用效果和患者生存情况。方法肾癌术后转移患者52例,其中31例肺转移患者采用干扰素α-2b+苹果酸舒尼替尼胶囊等治疗,21例骨转移患者应用苹果酸舒尼替尼胶囊+双膦酸盐+转化生长因子β1等治疗;观察临床疗效及治疗后6、12、36个月生存率。结果靶向药物治疗后,肺转移患者疾病缓解率为19.35%,治疗总有效率41.94%,生活质量改善率16.13%,生活质量改善总有效率70.97%;骨转移患者疾病缓解率为14.29%,治疗总有效率38.10%,生活质量改善率14.29%,生活质量改善总有效率76.19%;肺转移患者治疗后6、12、36个月生存率分别为77.41%、41.94%、19.35%,骨转移患者分别为76.19%、42.86%、19.05%。结论分子靶向治疗肾癌肺或骨转移的远期疗效差,但可提高患者生存质量。
Objective To investigate the effect of molecular targeted therapy of different metastatic organs in renal cell carcinoma and the survival of patients. Methods Fifty-two patients with postoperative metastasis of renal cell carcinoma were treated with interferon alfa-2b and sunitinib malate in 31 patients with lung metastasis. 21 patients with bone metastasis were treated with sunitinib malate capsules and bisphosphonates + TGF-β1 and other treatment; observe the clinical efficacy and survival rate 6,12,36 months after treatment. Results After the drug therapy, the response rate of patients with lung metastasis was 19.35%, the total effective rate was 41.94%, the quality of life improvement rate was 16.13%, and the total effective rate of life quality improvement was 70.97%. The disease response rate of patients with bone metastasis was 14.29% The total effective rate of treatment was 38.10%, the quality of life improvement rate was 14.29% and the total effective rate of life quality improvement was 76.19%. The survival rates of patients with lung metastasis at 6, 12, and 36 months after treatment were 77.41%, 41.94% and 19.35% Patients were 76.19%, 42.86%, 19.05% respectively. Conclusion The long-term efficacy of molecular targeted therapy for the treatment of lung cancer or bone metastasis is poor, but it can improve the quality of life of patients.